Skip to content

Supplier News

Heartland to buy Splenda brand from J&J

Heartland to buy Splenda brand from J&J

Heartland Food Products Group plans to acquire the Splenda low-calorie sweetener brand from McNeil Nutritionals LLC, a subsidiary of Johnson & Johnson Consumer Inc. Financial terms of the agreement weren’t disclosed. Heartland said the transaction is slated to close before the end of this year.

Upsher-Smith promotes Field to president

Upsher-Smith promotes Field to president

Rusty Field, chief commercial officer at Upsher-Smith Laboratories Inc., has been appointed as president of the company. Upsher-Smith said Monday that in the new role, Field will be responsible for delivering revenue and profitability to meet the pharmaceutical company’s growth objectives.

Switches will continue to be pacesetters in O-T-C arena

Switches will continue to be pacesetters in O-T-C arena

Growth of the U.S. over-the-counter medications market has been primarily driven by prescription-to-OTC switches And that expansion is likely to continue. Due to an increasingly favorable regulatory environment, Kline & Co.

Camber rolls out Baraclude generic

Camber rolls out Baraclude generic

Camber Pharmaceuticals Inc. has launched entecavir tablets, an antiviral medication. Camber said Friday that its entecavir product is available in 30- and 90-count bottle for the 0.5-mg strength and in 30-count bottles for the 1-mg dosage.

Galderma ships Epiduo Forte Gel

Galderma ships Epiduo Forte Gel

Galderma Laboratories has released Epiduo Forte Gel, a once-daily topical acne treatment, to retail pharmacies nationwide and in Puerto Rico. The medication, adapalene and benzoyl peroxide 0.3%/2.5%, received Food and Drug Administration approval last month.

Kirby Lester powers award-winning pharmacies

Kirby Lester powers award-winning pharmacies

The majority of award-winning community pharmacies use Kirby Lester prescription dispensing technology, according to an analysis by the pharmacy automation provider. Kirby Lester said Wednesday that of the U.S.

FDA OKs first drug for women’s sexual desire disorder

FDA OKs first drug for women’s sexual desire disorder

Sprout Pharmaceuticals Inc. has gained Food and Drug Administration clearance to market Addyi, which the company calls the first FDA-approved medication for hypoactive sexual desire disorder (HSDD) in women. Sprout said late Tuesday that Addyi (flibanserin, 100 mg) is slated to be released by Oct.